

Ian D Pavord

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449014/publications.pdf>

Version: 2024-02-01

224
papers

31,364
citations

10986

71
h-index

4432

172
g-index

231
all docs

231
docs citations

231
times ranked

17138
citing authors

#	ARTICLE	IF	CITATIONS
1	Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 60-66.	1.0	13
2	Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma". <i>Respiratory Medicine</i> , 2022, 191, 106088.	2.9	0
3	Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (<i>Respir. Med.</i> 2020). <i>Respiratory Medicine</i> , 2022, 191, 106106.	2.9	0
4	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. <i>Respiratory Medicine</i> , 2022, 191, 105991.	2.9	13
5	Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. <i>Thorax</i> , 2022, 77, 199-202.	5.6	70
6	Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 11-25.	10.7	109
7	From DREAM to REALITY and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 778-797.	5.7	25
8	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768.	6.7	8
9	Biological Therapies for Asthma. , 2022, , 411-434.		3
10	Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. <i>BMJ Open</i> , 2022, 12, e048537.	1.9	10
11	Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE). <i>ERJ Open Research</i> , 2022, 8, 00570-2021.	2.6	23
12	Fluticasone furoate: <scp>CAPTAIN</scp> of fluticasones in type 2 inflammatory asthma. <i>Respirology</i> , 2022, 27, 184-186.	2.3	6
13	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. <i>Cell</i> , 2022, 185, 916-938.e58.	28.9	164
14	Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 410-419.	3.8	21
15	Should we apply a treatable traits approach to asthma care?. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 390-397.	1.0	10
16	Asthma remission: what is it and how can it be achieved?. <i>European Respiratory Journal</i> , 2022, 60, 2102583.	6.7	61
17	Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies. <i>Microbiology Spectrum</i> , 2022, 10, e0227921.	3.0	5
18	Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. <i>Lancet, The</i> , 2022, 399, 909-923.	13.7	131

#	ARTICLE	IF	CITATIONS
19	Reply to: Challenging the paradigm. <i>Breathe</i> , 2022, 18, 210174.	1.3	0
20	Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. <i>BMJ Open</i> , 2022, 12, e058215.	1.9	7
21	Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population. <i>ERJ Open Research</i> , 2022, 8, 00606-2021.	2.6	12
22	Improving Care in Eosinophil-Associated Diseases: A Charter. <i>Advances in Therapy</i> , 2022, 39, 2323-2341.	2.9	6
23	Exacerbation Profile and Risk Factors in a Type-2 ^{low} Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	5.6	14
24	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker ^{high} and ^{low} severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.	5.7	11
25	Sub ² stratification of type ² high airway disease for therapeutic decision ² making: A ² “bomb ² ™ (blood) Tj ETog1 1 0.784314 rgB	2.3	18
26	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 17-24.	5.6	57
27	Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. <i>Thorax</i> , 2022, 77, 933-938.	5.6	6
28	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376.	5.7	7
29	Asthma in pregnancy: An update. <i>Obstetric Medicine</i> , 2021, 14, 135-144.	1.1	13
30	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1121-1132.e7.	3.8	19
31	Efficacy and safety of once-daily single-inhaler triple therapy (FF/LUMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 69-84.	10.7	135
32	Dupilumab is effective in type 2 ^{high} asthma patients receiving high ² dose inhaled corticosteroids at baseline. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 269-280.	5.7	25
33	Budesonide ² formoterol reliever therapy in intermittent <i>versus</i> mild persistent asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003064.	6.7	10
34	Composite type-2 biomarker strategy versus a symptom ² risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 57-68.	10.7	88
35	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	6.7	43
36	Balancing the needs of the many and the few: where next for adult asthma guidelines?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 786-794.	10.7	18

#	ARTICLE	IF	CITATIONS
37	A Proposed Revision of the Stepwise Treatment Algorithm in Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 100-103.	5.6	2
38	Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. Annual Review of Immunology, 2021, 39, 719-757.	21.8	69
39	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. Journal of Immunology, 2021, 206, 2714-2724.	0.8	8
40	Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2621-2624.	5.7	16
41	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International Journal of COPD, 2021, Volume 16, 1755-1770.	2.3	30
42	Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. European Respiratory Journal, 2021, 58, 2100413.	6.7	43
43	Management Strategies to Reduce Exacerbations in non-T2 Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2588-2597.	3.8	10
44	Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy, Asthma and Clinical Immunology, 2021, 17, 67.	2.0	3
45	Workup of Severe Asthma. Chest, 2021, 160, 2019-2029.	0.8	18
46	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.5	32
47	Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respiratory Medicine, the, 2021, 9, 909-923.	10.7	177
48	Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe, 2021, 17, 210053.	1.3	8
49	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	4.7	39
50	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 731-734.	5.6	40
51	Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3506-3509.e3.	3.8	0
52	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respiratory Medicine, the, 2021, 9, 1130-1140.	10.7	65
53	Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respiratory Medicine, the, 2021, 9, 1165-1173.	10.7	70
54	The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respiratory Medicine, the, 2021, 9, 1174-1184.	10.7	49

#	ARTICLE	IF	CITATIONS
55	Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. <i>Respiratory Medicine</i> , 2021, 187, 106572.	2.9	29
56	Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes. <i>Lancet, The</i> , 2021, 398, 1856-1858.	13.7	7
57	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 1656-1668.	27.0	183
58	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 516-526.	3.8	123
59	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a <i>Haemophilus</i> predominant subgroup. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 808-817.	5.7	33
60	Point-of-care biomarkers in asthma management: Time to move forward. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 995-997.	5.7	13
61	Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. <i>Journal of Asthma</i> , 2020, 57, 987-998.	1.7	21
62	COPD exacerbation phenotypes: The next frontier. <i>Respirology</i> , 2020, 25, 230-231.	2.3	2
63	ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. <i>European Respiratory Journal</i> , 2020, 55, 1901407.	6.7	26
64	Optimal Asthma Control: Time for a New Target. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1480-1487.	5.6	32
65	Anti-IL-4/IL-13 for the treatment of asthma: the story so far. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 283-294.	3.1	25
66	An expert consensus framework for asthma remission as a treatment goal. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 757-765.	2.9	144
67	Response to mepolizumab treatment is sustained across 4-weekly dosing periods. <i>ERJ Open Research</i> , 2020, 6, 00068-2020.	2.6	4
68	Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. <i>ERJ Open Research</i> , 2020, 6, 00284-2020.	2.6	40
69	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	2.6	33
70	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. <i>Trials</i> , 2020, 21, 718.	1.6	25
71	Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: practical considerations. <i>European Respiratory Journal</i> , 2020, 56, 2002809.	6.7	0
72	Biomarkers of Type 2 Airway Inflammation in Airway Disease: And Then There Were Two. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2640-2642.	3.8	4

#	ARTICLE	IF	CITATIONS
73	A golden age of asthma research. <i>European Respiratory Journal</i> , 2020, 56, 2003820.	6.7	2
74	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. <i>European Respiratory Journal</i> , 2020, 55, 2000351.	6.7	81
75	Achieving the balance between evidence and simplicity. <i>European Respiratory Journal</i> , 2020, 55, 2000651.	6.7	0
76	Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design. <i>ERJ Open Research</i> , 2020, 6, 00333-2019.	2.6	2
77	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680.	10.7	81
78	Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2020, 55, 1902150.	6.7	26
79	Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients With Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, A521.	2.9	3
80	Blood Eosinophil-directed Management of Airway Disease. The Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 637-639.	5.6	10
81	Targeted biologic therapy for asthma. <i>British Medical Bulletin</i> , 2020, 133, 16-35.	6.9	5
82	Blood eosinophil count predicts treatment failure and hospital readmission for COPD. <i>ERJ Open Research</i> , 2020, 6, 00188-2020.	2.6	7
83	Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 701-711.	3.4	14
84	Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1308-1312.	5.6	87
85	Reply to Boulet and Nair: Inhaled Corticosteroids and Adult Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1557-1558.	5.6	0
86	Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 183-194.	3.4	23
87	Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. <i>Clinical and Translational Allergy</i> , 2019, 9, 41.	3.2	46
88	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. <i>European Respiratory Journal</i> , 2019, 54, 1900108.	6.7	12
89	Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1722-1726.e10.	2.9	5
90	Prospective observational study in patients with obstructive lung disease: NOVELTY design. <i>ERJ Open Research</i> , 2019, 5, 00036-2018.	2.6	29

#	ARTICLE	IF	CITATIONS
91	<p>The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD</p>. International Journal of COPD, 2019, Volume 14, 971-977.	2.3	8
92	Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Respiratory Medicine, 2019, 154, 27-33.	2.9	4
93	Controlled Trial of BudesonideâFormoterol as Needed for Mild Asthma. New England Journal of Medicine, 2019, 380, 2020-2030.	27.0	308
94	Asthma progression and mortality: the role of inhaled corticosteroids. European Respiratory Journal, 2019, 54, 1900491.	6.7	96
95	Measuring lung function in airways diseases: current and emerging techniques. Thorax, 2019, 74, 797-805.	5.6	21
96	Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. European Respiratory Journal, 2019, 53, 1802058.	6.7	177
97	Fevipirant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. Journal of Allergy and Clinical Immunology, 2019, 143, 2329-2333.	2.9	11
98	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
99	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1430-1436.	3.8	3
100	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 823-829.	5.6	31
101	DP ₂ antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Science Translational Medicine, 2019, 11, .	12.4	57
102	Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma. BMC Pulmonary Medicine, 2019, 19, 264.	2.0	7
103	Severe T2-high asthma in the biologics era: European experts' opinion. European Respiratory Review, 2019, 28, 190054.	7.1	32
104	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.2	11
105	Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1471-1477.	5.6	87
106	Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 454-464.	5.6	115
107	Oral corticosteroid-dependent asthma. Current Opinion in Pulmonary Medicine, 2019, 25, 51-58.	2.6	26
108	The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate. Turkish Thoracic Journal, 2019, 20, 198-202.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations. <i>New England Journal of Medicine</i> , 2018, 378, 902-910.	27.0	119
110	Rebuttal From Dr Pavord. <i>Chest</i> , 2018, 153, 786-787.	0.8	0
111	COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% \hat{A} % \hat{A} FEV1 \hat{A} < 50% Predicted) COPD? No. <i>Chest</i> , 2018, 153, 782-784.	0.8	4
112	Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 874-882.e4.	3.8	19
113	Physiotherapy breathing retraining for asthma: a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 19-28.	10.7	97
114	"We can't diagnose asthma until <insert arbitrary age>". <i>Archives of Disease in Childhood</i> , 2018, 103, 729-731.	1.9	10
115	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 737-748.	2.9	129
116	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2027-2036.e12.	2.9	124
117	Blood eosinophil levels as a biomarker in COPD. <i>Respiratory Medicine</i> , 2018, 138, 21-31.	2.9	86
118	Associations between blood eosinophils and decline in lung function among adults with and without asthma. <i>European Respiratory Journal</i> , 2018, 51, 1702536.	6.7	93
119	Treating asthma exacerbations in athletes: TUE or not TUE?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 8-10.	10.7	6
120	After asthma: redefining airways diseases. <i>Lancet</i> , 2018, 391, 350-400.	13.7	744
121	A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. <i>Respiratory Medicine</i> , 2018, 134, 117-123.	2.9	24
122	Exacerbations of severe asthma in patients treated with mepolizumab. <i>European Respiratory Journal</i> , 2018, 52, 1801127.	6.7	16
123	Do we really need a new classification of airway diseases?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 891-893.	10.7	5
124	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2486-2496.	27.0	1,253
125	Biologics and chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1983-1991.	2.9	28
126	GLUCOLD, eosinophils and chronic obstructive pulmonary disease. <i>Respirology</i> , 2018, 23, 966-967.	2.3	1

#	ARTICLE	IF	CITATIONS
127	Will precision medicine become an effective tool for airway disease?. <i>Personalized Medicine</i> , 2018, 15, 243-245.	1.5	0
128	Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. <i>PLoS ONE</i> , 2018, 13, e0201143.	2.5	28
129	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. <i>Trials</i> , 2018, 19, 5.	1.6	26
130	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. <i>Mucosal Immunology</i> , 2018, 11, 1408-1419.	6.0	46
131	Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST. <i>Health Technology Assessment</i> , 2018, 22, 1-82.	2.8	4
132	Cysteinyl leukotriene E 4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D 2 and epithelial cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1090-1100.e11.	2.9	130
133	The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β_2 -agonists in the United Kingdom: a cross-sectional analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 17.	2.6	64
134	A new approach to the classification and management of airways diseases: identification of treatable traits. <i>Clinical Science</i> , 2017, 131, 1027-1043.	4.3	30
135	Severe eosinophilic asthma: a roadmap to a consensus. <i>European Respiratory Journal</i> , 2017, 49, 1700634.	6.7	143
136	Eosinophils in COPD: just another biomarker?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 747-759.	10.7	160
137	Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook. <i>BioDrugs</i> , 2017, 31, 93-103.	4.6	20
138	Mepolizumab, quality of life, and severe eosinophilic asthma. <i>Lancet Respiratory Medicine</i> , 2017, 5, 362-363.	10.7	5
139	Precision medicine in airway diseases: moving to clinical practice. <i>European Respiratory Journal</i> , 2017, 50, 1701655.	6.7	151
140	Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1613-1629.	27.0	397
141	After the asthmas: Star Wars and Star Trek. <i>European Respiratory Journal</i> , 2017, 50, 1701362.	6.7	4
142	Blood eosinophil count and exacerbation risk in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700761.	6.7	64
143	The Objective Assessment of Cough Frequency in Bronchiectasis. <i>Lung</i> , 2017, 195, 575-585.	3.3	18
144	Multidimensional assessment of severe asthma: A systematic review and meta-analysis. <i>Respirology</i> , 2017, 22, 1262-1275.	2.3	82

#	ARTICLE	IF	CITATIONS
145	Biomarkers for severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1509-1518.	2.9	180
146	Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 745-747.	2.9	4
147	Azithromycin in uncontrolled asthma. <i>Lancet, The</i> , 2017, 390, 629-630.	13.7	5
148	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1167-1175.e2.	2.9	78
149	Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial. <i>Journal of Thoracic Disease</i> , 2017, 9, 1864-1872.	1.4	8
150	A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults. <i>Health Technology Assessment</i> , 2017, 21, 1-162.	2.8	13
151	First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16061.	2.6	20
152	Step 4: stick or twist? A review of asthma therapy. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000143.	3.0	3
153	Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. <i>European Respiratory Journal</i> , 2016, 47, 1299-1303.	6.7	40
154	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 549-556.	10.7	433
155	What can we learn from blood granulocyte patterns in patients with asthma?. <i>European Respiratory Journal</i> , 2016, 48, 976-978.	6.7	5
156	Lessons from LAVOLTA. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 764-765.	10.7	2
157	Fevipirant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 699-707.	10.7	220
158	Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 731-741.	10.7	147
159	Emerging Biologics in Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 609-623.	1.9	9
160	A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. <i>European Respiratory Journal</i> , 2016, 48, 320-330.	6.7	77
161	FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. <i>Trials</i> , 2016, 17, 499.	1.6	4
162	Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 585-592.	10.7	53

#	ARTICLE	IF	CITATIONS
163	Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β -2-Agonists" Applied Health Economics and Health Policy, 2016, 14, 117-118.	2.1	0
164	Blood eosinophils and inhaled corticosteroid/long-acting β -2 agonist efficacy in COPD. Thorax, 2016, 71, 118-125.	5.6	288
165	Inhaled corticosteroid dose-response on blood eosinophils in asthma " Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e1-e2.	10.7	1
166	Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. European Respiratory Journal, 2016, 47, 981-984.	6.7	18
167	Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest, 2016, 150, 320-328.	0.8	125
168	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
169	Predictors of objective cough frequency in pulmonary sarcoidosis. European Respiratory Journal, 2016, 47, 1461-1471.	6.7	43
170	Morbidity associated with oral corticosteroids in patients with severe asthma. Thorax, 2016, 71, 302-304.	5.6	15
171	Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review. European Respiratory Journal, 2016, 47, 751-768.	6.7	72
172	Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax, 2016, 71, 187-189.	5.6	78
173	Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations. Chest, 2015, 147, 46-55.	0.8	74
174	The asthmas in 2015 and beyond: a Lancet Commission. Lancet, The, 2015, 385, 1273-1275.	13.7	29
175	Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Therapeutic Advances in Respiratory Disease, 2015, 9, 135-145.	2.6	39
176	Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? " Authors' reply. Lancet Respiratory Medicine,the, 2015, 3, e27.	10.7	7
177	Biological clustering supports both "Dutch"and "British" hypotheses of asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 135, 63-72.e10.	2.9	111
178	Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation. European Respiratory Review, 2015, 24, 204-215.	7.1	103
179	Two Lovely Black Eyes; Oh, what a surprise!. Thorax, 2015, 70, 609-610.	5.6	13
180	Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respiratory Medicine,the, 2015, 3, 435-442.	10.7	583

#	ARTICLE	IF	CITATIONS
181	Asthma diagnosis: addressing the challenges. <i>Lancet Respiratory Medicine</i> , 2015, 3, 339-341.	10.7	12
182	Biomarkers and inhaled corticosteroid responsiveness in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 884-885.	2.9	5
183	Year in review 2014. Paediatric and adult clinical studies. <i>Thorax</i> , 2015, 70, 368-372.	5.6	0
184	A randomised controlled trial of small particle inhaled steroids in refractory eosinophilic asthma (SPIRA). <i>Thorax</i> , 2015, 70, 559-565.	5.6	18
185	Monitoring asthma in children. <i>European Respiratory Journal</i> , 2015, 45, 906-925.	6.7	114
186	Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. <i>Lancet Respiratory Medicine</i> , 2015, 3, 769-781.	10.7	346
187	Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. <i>Lancet Respiratory Medicine</i> , 2015, 3, 849-858.	10.7	443
188	A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. <i>European Respiratory Journal</i> , 2015, 46, 1021-1032.	6.7	85
189	Look back with (some) anger, and a lot of pleasure. <i>Thorax</i> , 2015, 70, 819-821.	5.6	1
190	Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. <i>Health Technology Assessment</i> , 2015, 19, 1-330.	2.8	54
191	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. <i>European Respiratory Journal</i> , 2014, 44, 789-791.	6.7	141
192	<i>Thorax</i> : the prostate years. <i>Thorax</i> , 2014, 69, 3-4.	5.6	0
193	Current evidence and future research needs for FeNO measurement in respiratory diseases. <i>Respiratory Medicine</i> , 2014, 108, 830-841.	2.9	157
194	A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. <i>European Respiratory Journal</i> , 2014, 44, 1149-1155.	6.7	202
195	Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1189-1197.	27.0	1,331
196	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1198-1207.	27.0	1,807
197	Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 921-923.	2.9	150
198	Effectiveness of voriconazole in the treatment of <i>Aspergillus fumigatus</i> -associated asthma (EVITA3) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.9	74

#	ARTICLE	IF	CITATIONS
199	Safety of bronchial thermoplasty in patients with severe refractory asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 402-407.	1.0	91
200	Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 828-829.	2.9	34
201	Complex airway disease: an approach to assessment and management. <i>Lancet Respiratory Medicine</i> , 2013, 1, 84-90.	10.7	16
202	Eosinophilic Phenotypes of Airway Disease. <i>Annals of the American Thoracic Society</i> , 2013, 10, S143-S149.	3.2	46
203	A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 283-287.	2.3	40
204	Four-Hour Cough Frequency Monitoring in Chronic Cough. <i>Chest</i> , 2012, 142, 1237-1243.	0.8	22
205	Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 48-55.	5.6	499
206	Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 380, 651-659.	13.7	1,849
207	Primary Human Airway Epithelial Cell-Dependent Inhibition of Human Lung Mast Cell Degranulation. <i>PLoS ONE</i> , 2012, 7, e43545.	2.5	37
208	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 662-671.	5.6	847
209	Eosinophil protein in airway macrophages: A novel biomarker of eosinophilic inflammation in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 61-69.e3.	2.9	76
210	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 59-99.	5.6	1,591
211	Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1083-1089.e7.	2.9	64
212	Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2009, 360, 973-984.	27.0	1,672
213	Cluster Analysis and Clinical Asthma Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 218-224.	5.6	1,727
214	Management of chronic cough. <i>Lancet, The</i> , 2008, 371, 1375-1384.	13.7	144
215	Inflammometry to assess airway diseases. <i>Lancet, The</i> , 2008, 372, 1017-1019.	13.7	72
216	The Use of Exhaled Nitric Oxide in the Management of Asthma. <i>Journal of Asthma</i> , 2008, 45, 523-531.	1.7	25

#	ARTICLE	IF	CITATIONS
217	Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1185-1191.	5.6	387
218	Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax, 2007, 62, 1043-1049.	5.6	396
219	Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma. Respiratory Research, 2007, 8, 67.	3.6	11
220	Cough and asthma. Pulmonary Pharmacology and Therapeutics, 2004, 17, 399-402.	2.6	22
221	Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, The, 2002, 360, 1715-1721.	13.7	1,598
222	Mast-Cell Infiltration of Airway Smooth Muscle in Asthma. New England Journal of Medicine, 2002, 346, 1699-1705.	27.0	1,147
223	Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 2000, 356, 1480-1485.	13.7	514
224	Non-eosinophilic corticosteroid unresponsive asthma. Lancet, The, 1999, 353, 2213-2214.	13.7	473